While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...